Insmed (NASDAQ:INSM) Price Target Raised to $208.00

Insmed (NASDAQ:INSM) had its price target increased by equities researchers at Stifel Nicolaus from $205.00 to $208.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price would indicate a potential upside of 49.53% from the company’s current price.

Several other equities analysts also recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a report on Thursday, January 22nd. Royal Bank Of Canada increased their price objective on shares of Insmed from $197.00 to $200.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. The Goldman Sachs Group raised their price objective on shares of Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Mizuho lowered their target price on shares of Insmed from $211.00 to $204.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 24th. Finally, Truist Financial set a $205.00 target price on shares of Insmed in a report on Monday, January 12th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $204.62.

Insmed Stock Performance

Shares of NASDAQ INSM traded down $4.88 during trading on Tuesday, hitting $139.11. The company had a trading volume of 285,640 shares, compared to its average volume of 2,444,458. Insmed has a 12 month low of $60.40 and a 12 month high of $212.75. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The firm has a market capitalization of $29.98 billion, a P/E ratio of -21.70 and a beta of 1.13. The stock has a 50 day simple moving average of $151.48 and a 200 day simple moving average of $166.27.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The company had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The company’s revenue was up 152.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.32) earnings per share. As a group, analysts anticipate that Insmed will post -4.56 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO William Lewis sold 19,215 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the sale, the chief executive officer owned 306,891 shares of the company’s stock, valued at $51,864,579. This represents a 5.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $175.20, for a total transaction of $15,293,208.00. Following the sale, the insider directly owned 41,754 shares in the company, valued at approximately $7,315,300.80. The trade was a 67.64% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 189,651 shares of company stock valued at $31,533,654. 3.00% of the stock is currently owned by insiders.

Institutional Trading of Insmed

A number of large investors have recently made changes to their positions in the business. Hsbc Holdings PLC raised its position in shares of Insmed by 8,052.6% during the 4th quarter. Hsbc Holdings PLC now owns 123,267 shares of the biopharmaceutical company’s stock valued at $21,493,000 after buying an additional 121,755 shares in the last quarter. Rockefeller Capital Management L.P. grew its position in Insmed by 88.2% in the fourth quarter. Rockefeller Capital Management L.P. now owns 16,775 shares of the biopharmaceutical company’s stock worth $2,920,000 after acquiring an additional 7,863 shares in the last quarter. Corient Private Wealth LLC grew its position in Insmed by 34.1% in the fourth quarter. Corient Private Wealth LLC now owns 20,865 shares of the biopharmaceutical company’s stock worth $3,631,000 after acquiring an additional 5,305 shares in the last quarter. Keenan LLC bought a new stake in Insmed during the fourth quarter worth approximately $369,000. Finally, Reflection Asset Management purchased a new stake in Insmed during the fourth quarter valued at approximately $30,000.

Key Headlines Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Company announces positive topline Phase 3b ENCORE results: the study met its primary and multiplicity‑controlled secondary endpoints, showed clinically meaningful respiratory symptom and culture conversion improvements, and Insmed plans to file a supplemental NDA in the second half of 2026 and submit data to Japan’s PMDA. PR Newswire: Insmed Announces Positive Topline Results
• Positive Sentiment: Market response and coverage show immediate investor enthusiasm: multiple outlets report a jump in shares after the trial data, highlighting a larger market opportunity for ARIKAYCE in MAC lung disease. Proactive: Insmed shares rise on positive late-stage trial results
• Positive Sentiment: Bank of America raised its price target to $213 and kept a Buy rating, signaling bullish analyst conviction and implying substantial upside from current levels. Benzinga: BofA raises price target
• Neutral Sentiment: Wells Fargo trimmed its price target from $208 to $175 but maintained an Overweight rating — a mixed read: analysts are still positive on the story but some see less near‑term upside. Benzinga: Wells Fargo lowers price target
• Neutral Sentiment: Insmed hosted an investor/shareholder call; the transcript provides additional detail and management color but did not introduce new clinical surprises beyond the topline release. Seeking Alpha: Shareholder/Analyst Call Transcript
• Negative Sentiment: Insider selling: CEO reported a sale of approximately $1.54M of INSM stock, which may raise governance or timing concerns for some investors despite the positive clinical news. American Banking News: Insider Selling

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.